Eotaxin-1 and mucosal eosinophil abundance predict treatment response to vedolizumab in Inflammatory Bowel Disease

Ruben Y. Gabriëls; Arno R. Bourgonje; Julius Z. H. von Martels; Guido Trentadue; Tjasso Blokzijl; Hendrik M. Dullemen, van; E. A. M. Festen; Marijn C. Visschedijk; Rinse K. Weersma; Gürsah Kats-Ugurlu; Klaas Nico Faber; G. Dijkstra

Eotaxin-1 and mucosal eosinophil abundance predict treatment response to vedolizumab in Inflammatory Bowel Disease

Ruben Y. Gabriëls, Arno R. Bourgonje, Julius Z. H. von Martels, Guido Trentadue, Tjasso Blokzijl, Hendrik M. Dullemen, van, E. A. M. Festen, Marijn C. Visschedijk, Rinse K. Weersma, Gürsah Kats-Ugurlu, Klaas Nico Faber, G. Dijkstra

Onderzoeksoutput › Academic

Originele taal-2	English
Tijdschrift	United European Gastroenterology Journal
Status	Published - okt-2019

Document onder embargo

Eotaxin-1 and mucosal eosinophil abundance predict treatment response to vedolizumab in inflammatory Bowel Disease
Final publisher's version, 106 KB
Kopie aanvragen

Citeer dit

Gabriëls, R. Y., Bourgonje, A. R., von Martels, J. Z. H., Trentadue, G., Blokzijl, T., Dullemen, van, H. M., Festen, E. A. M., Visschedijk, M. C., Weersma, R. K., Kats-Ugurlu, G., Faber, K. N., & Dijkstra, G. (2019). Eotaxin-1 and mucosal eosinophil abundance predict treatment response to vedolizumab in Inflammatory Bowel Disease. United European Gastroenterology Journal.

Gabriëls, Ruben Y. ; Bourgonje, Arno R. ; von Martels, Julius Z. H. ; Trentadue, Guido ; Blokzijl, Tjasso ; Dullemen, van, Hendrik M. ; Festen, E. A. M. ; Visschedijk, Marijn C. ; Weersma, Rinse K. ; Kats-Ugurlu, Gürsah ; Faber, Klaas Nico ; Dijkstra, G. / Eotaxin-1 and mucosal eosinophil abundance predict treatment response to vedolizumab in Inflammatory Bowel Disease. In: United European Gastroenterology Journal. 2019.

@article{76c123352e414a31ac1c6c7dd9238ec2,

title = "Eotaxin-1 and mucosal eosinophil abundance predict treatment response to vedolizumab in Inflammatory Bowel Disease",

author = "Gabri{\"e}ls, {Ruben Y.} and Bourgonje, {Arno R.} and {von Martels}, {Julius Z. H.} and Guido Trentadue and Tjasso Blokzijl and {Dullemen, van}, {Hendrik M.} and Festen, {E. A. M.} and Visschedijk, {Marijn C.} and Weersma, {Rinse K.} and G{\"u}rsah Kats-Ugurlu and Faber, {Klaas Nico} and G. Dijkstra",

year = "2019",

month = oct,

language = "English",

journal = "United European Gastroenterology Journal",

issn = "2050-6406",

publisher = "SAGE Publications Inc.",

}

Eotaxin-1 and mucosal eosinophil abundance predict treatment response to vedolizumab in Inflammatory Bowel Disease. / Gabriëls, Ruben Y.; Bourgonje, Arno R.; von Martels, Julius Z. H.; Trentadue, Guido; Blokzijl, Tjasso; Dullemen, van, Hendrik M.; Festen, E. A. M.; Visschedijk, Marijn C.; Weersma, Rinse K.; Kats-Ugurlu, Gürsah ; Faber, Klaas Nico ; Dijkstra, G.

In: United European Gastroenterology Journal, 10.2019.

Onderzoeksoutput › Academic

TY - JOUR

T1 - Eotaxin-1 and mucosal eosinophil abundance predict treatment response to vedolizumab in Inflammatory Bowel Disease

AU - Gabriëls, Ruben Y.

AU - Bourgonje, Arno R.

AU - von Martels, Julius Z. H.

AU - Trentadue, Guido

AU - Blokzijl, Tjasso

AU - Dullemen, van, Hendrik M.

AU - Festen, E. A. M.

AU - Visschedijk, Marijn C.

AU - Weersma, Rinse K.

AU - Kats-Ugurlu, Gürsah

AU - Faber, Klaas Nico

AU - Dijkstra, G.

PY - 2019/10

Y1 - 2019/10

M3 - Meeting Abstract

JO - United European Gastroenterology Journal

JF - United European Gastroenterology Journal

SN - 2050-6406

ER -